dc.contributor.author
Ciruela Alférez, Francisco
dc.contributor.author
Fuxe, Kjell
dc.contributor.author
Illes, Peter
dc.contributor.author
Ulrich, Henning
dc.contributor.author
Caciagli, Francesco
dc.date.issued
2025-09-19T08:46:50Z
dc.date.issued
2025-09-19T08:46:50Z
dc.date.issued
2021-09-14
dc.date.issued
2025-09-19T08:46:50Z
dc.identifier
https://hdl.handle.net/2445/223267
dc.description.abstract
The “purinergic signaling” term was coined in 1972 by Geoffrey Burnstock Burnstock et al. after demonstrating that adenosine 5’-triphosphate (ATP) is a transmitter in nonadrenergic, noncholinergic inhibitory nerves innervating the guinea-pig taenia coli (Burnstock et al., 1966). This signaling system, which is ubiquitously expressed in every organ and system of the body, comprises various ecto-, soluble and intracellularly localized enzymes, nucleoside transporters, and G protein-coupled and ligand-gated cation channel receptors. Through the purinergic signaling
system cells can maintain basal adenine and guanine-based purines at certain steady-state levels, thereby contributing to preserve the purines-dependent cellular homeostasis.
dc.format
application/pdf
dc.publisher
Frontiers Media
dc.relation
Reproducció del document publicat a: https://doi.org/10.3389/fphar.2021.768923
dc.relation
Frontiers in Pharmacology, 2021, vol. 12
dc.relation
https://doi.org/10.3389/fphar.2021.768923
dc.rights
cc-by (c) Ciruela, F. et al., 2021
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject
Trifosfat d'adenosina
dc.subject
Adenosine triphospahatase
dc.title
Editorial: Purinergic Signaling 2020: the State-of-The-Art commented by the members of the Italian Purine Club
dc.type
info:eu-repo/semantics/publishedVersion
dc.type
info:eu-repo/semantics/article